Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes

Amanda L. Horton, Yinglei Lai, Dwight J. Rouse, Catherine Y. Spong, Kenneth J. Leveno, Michael W. Varner, Brian M. Mercer, Jay D. Iams, Ronald J. Wapner, Yoram Sorokin, John M. Thorp, Susan M. Ramin, Fergal D. Malone, Mary J. O'Sullivan, Gary Hankins, Steve N. Caritis

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective This study aims to evaluate whether magnesium sulfate administration for neuroprotection prolongs latency in women with preterm premature rupture of membranes (PPROM) between 24 and 316/7 weeks' gestation. Study Design This is a secondary analysis of a randomized controlled trial of magnesium sulfate for prevention of cerebral palsy. Gravid women with a singleton pregnancy between 24 and 316/7 weeks' gestation with PPROM without evidence of labor were randomized to receive magnesium sulfate, administered intravenously as a 6-g bolus followed by a constant infusion of 2 g per hour up to 12 hours, or placebo. Maternal outcomes for this analysis were delivery in less than 48 hours and in less than 7 days from randomization. Neonatal outcomes included a composite of respiratory distress syndrome, interventricular hemorrhage grades 3 or 4, periventricular leukomalacia, sepsis, necrotizing enterocolitis, retinopathy of prematurity, or death. Results A total of 1,259 women were included. The rate of delivery < 48 hours was not different in the magnesium sulfate and the placebo groups (22.2 and 20.7%, p= 0.51). Delivery< 7 days was similar between groups (55.4 and 51.4%, p = 0.16). Median latency was also similar between groups (median [interquartile range], 6.0 days [range, 2.4-13.8 days] and 6.6 days [range, 2.4-15.1 days], p= 0.29). Composite neonatal outcomes did not differ between groups. Conclusion Magnesium sulfate administration given for neuroprotection in women with a singleton gestation with PPROM and without labor before 32 weeks does not impact latency

Original languageEnglish (US)
Pages (from-to)387-392
Number of pages6
JournalAmerican Journal of Perinatology
Volume32
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Magnesium Sulfate
Pregnancy
Placebos
Periventricular Leukomalacia
Retinopathy of Prematurity
Necrotizing Enterocolitis
Cerebral Palsy
Random Allocation
Sepsis
Randomized Controlled Trials
Mothers
Preterm Premature Rupture of the Membranes
Neuroprotection
Hemorrhage

Keywords

  • latency
  • magnesium sulfate
  • neuroprotection
  • preterm premature rupture of membranes

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. / Horton, Amanda L.; Lai, Yinglei; Rouse, Dwight J.; Spong, Catherine Y.; Leveno, Kenneth J.; Varner, Michael W.; Mercer, Brian M.; Iams, Jay D.; Wapner, Ronald J.; Sorokin, Yoram; Thorp, John M.; Ramin, Susan M.; Malone, Fergal D.; O'Sullivan, Mary J.; Hankins, Gary; Caritis, Steve N.

In: American Journal of Perinatology, Vol. 32, No. 4, 2014, p. 387-392.

Research output: Contribution to journalArticle

Horton, AL, Lai, Y, Rouse, DJ, Spong, CY, Leveno, KJ, Varner, MW, Mercer, BM, Iams, JD, Wapner, RJ, Sorokin, Y, Thorp, JM, Ramin, SM, Malone, FD, O'Sullivan, MJ, Hankins, G & Caritis, SN 2014, 'Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes', American Journal of Perinatology, vol. 32, no. 4, pp. 387-392. https://doi.org/10.1055/s-0034-1387930
Horton, Amanda L. ; Lai, Yinglei ; Rouse, Dwight J. ; Spong, Catherine Y. ; Leveno, Kenneth J. ; Varner, Michael W. ; Mercer, Brian M. ; Iams, Jay D. ; Wapner, Ronald J. ; Sorokin, Yoram ; Thorp, John M. ; Ramin, Susan M. ; Malone, Fergal D. ; O'Sullivan, Mary J. ; Hankins, Gary ; Caritis, Steve N. / Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. In: American Journal of Perinatology. 2014 ; Vol. 32, No. 4. pp. 387-392.
@article{6ec66ca4acfc4f0da23ee5bdd3bfdc5e,
title = "Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes",
abstract = "Objective This study aims to evaluate whether magnesium sulfate administration for neuroprotection prolongs latency in women with preterm premature rupture of membranes (PPROM) between 24 and 316/7 weeks' gestation. Study Design This is a secondary analysis of a randomized controlled trial of magnesium sulfate for prevention of cerebral palsy. Gravid women with a singleton pregnancy between 24 and 316/7 weeks' gestation with PPROM without evidence of labor were randomized to receive magnesium sulfate, administered intravenously as a 6-g bolus followed by a constant infusion of 2 g per hour up to 12 hours, or placebo. Maternal outcomes for this analysis were delivery in less than 48 hours and in less than 7 days from randomization. Neonatal outcomes included a composite of respiratory distress syndrome, interventricular hemorrhage grades 3 or 4, periventricular leukomalacia, sepsis, necrotizing enterocolitis, retinopathy of prematurity, or death. Results A total of 1,259 women were included. The rate of delivery < 48 hours was not different in the magnesium sulfate and the placebo groups (22.2 and 20.7{\%}, p= 0.51). Delivery< 7 days was similar between groups (55.4 and 51.4{\%}, p = 0.16). Median latency was also similar between groups (median [interquartile range], 6.0 days [range, 2.4-13.8 days] and 6.6 days [range, 2.4-15.1 days], p= 0.29). Composite neonatal outcomes did not differ between groups. Conclusion Magnesium sulfate administration given for neuroprotection in women with a singleton gestation with PPROM and without labor before 32 weeks does not impact latency",
keywords = "latency, magnesium sulfate, neuroprotection, preterm premature rupture of membranes",
author = "Horton, {Amanda L.} and Yinglei Lai and Rouse, {Dwight J.} and Spong, {Catherine Y.} and Leveno, {Kenneth J.} and Varner, {Michael W.} and Mercer, {Brian M.} and Iams, {Jay D.} and Wapner, {Ronald J.} and Yoram Sorokin and Thorp, {John M.} and Ramin, {Susan M.} and Malone, {Fergal D.} and O'Sullivan, {Mary J.} and Gary Hankins and Caritis, {Steve N.}",
year = "2014",
doi = "10.1055/s-0034-1387930",
language = "English (US)",
volume = "32",
pages = "387--392",
journal = "American Journal of Perinatology",
issn = "0735-1631",
publisher = "Thieme Medical Publishers",
number = "4",

}

TY - JOUR

T1 - Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes

AU - Horton, Amanda L.

AU - Lai, Yinglei

AU - Rouse, Dwight J.

AU - Spong, Catherine Y.

AU - Leveno, Kenneth J.

AU - Varner, Michael W.

AU - Mercer, Brian M.

AU - Iams, Jay D.

AU - Wapner, Ronald J.

AU - Sorokin, Yoram

AU - Thorp, John M.

AU - Ramin, Susan M.

AU - Malone, Fergal D.

AU - O'Sullivan, Mary J.

AU - Hankins, Gary

AU - Caritis, Steve N.

PY - 2014

Y1 - 2014

N2 - Objective This study aims to evaluate whether magnesium sulfate administration for neuroprotection prolongs latency in women with preterm premature rupture of membranes (PPROM) between 24 and 316/7 weeks' gestation. Study Design This is a secondary analysis of a randomized controlled trial of magnesium sulfate for prevention of cerebral palsy. Gravid women with a singleton pregnancy between 24 and 316/7 weeks' gestation with PPROM without evidence of labor were randomized to receive magnesium sulfate, administered intravenously as a 6-g bolus followed by a constant infusion of 2 g per hour up to 12 hours, or placebo. Maternal outcomes for this analysis were delivery in less than 48 hours and in less than 7 days from randomization. Neonatal outcomes included a composite of respiratory distress syndrome, interventricular hemorrhage grades 3 or 4, periventricular leukomalacia, sepsis, necrotizing enterocolitis, retinopathy of prematurity, or death. Results A total of 1,259 women were included. The rate of delivery < 48 hours was not different in the magnesium sulfate and the placebo groups (22.2 and 20.7%, p= 0.51). Delivery< 7 days was similar between groups (55.4 and 51.4%, p = 0.16). Median latency was also similar between groups (median [interquartile range], 6.0 days [range, 2.4-13.8 days] and 6.6 days [range, 2.4-15.1 days], p= 0.29). Composite neonatal outcomes did not differ between groups. Conclusion Magnesium sulfate administration given for neuroprotection in women with a singleton gestation with PPROM and without labor before 32 weeks does not impact latency

AB - Objective This study aims to evaluate whether magnesium sulfate administration for neuroprotection prolongs latency in women with preterm premature rupture of membranes (PPROM) between 24 and 316/7 weeks' gestation. Study Design This is a secondary analysis of a randomized controlled trial of magnesium sulfate for prevention of cerebral palsy. Gravid women with a singleton pregnancy between 24 and 316/7 weeks' gestation with PPROM without evidence of labor were randomized to receive magnesium sulfate, administered intravenously as a 6-g bolus followed by a constant infusion of 2 g per hour up to 12 hours, or placebo. Maternal outcomes for this analysis were delivery in less than 48 hours and in less than 7 days from randomization. Neonatal outcomes included a composite of respiratory distress syndrome, interventricular hemorrhage grades 3 or 4, periventricular leukomalacia, sepsis, necrotizing enterocolitis, retinopathy of prematurity, or death. Results A total of 1,259 women were included. The rate of delivery < 48 hours was not different in the magnesium sulfate and the placebo groups (22.2 and 20.7%, p= 0.51). Delivery< 7 days was similar between groups (55.4 and 51.4%, p = 0.16). Median latency was also similar between groups (median [interquartile range], 6.0 days [range, 2.4-13.8 days] and 6.6 days [range, 2.4-15.1 days], p= 0.29). Composite neonatal outcomes did not differ between groups. Conclusion Magnesium sulfate administration given for neuroprotection in women with a singleton gestation with PPROM and without labor before 32 weeks does not impact latency

KW - latency

KW - magnesium sulfate

KW - neuroprotection

KW - preterm premature rupture of membranes

UR - http://www.scopus.com/inward/record.url?scp=84925359388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925359388&partnerID=8YFLogxK

U2 - 10.1055/s-0034-1387930

DO - 10.1055/s-0034-1387930

M3 - Article

C2 - 25241107

AN - SCOPUS:84925359388

VL - 32

SP - 387

EP - 392

JO - American Journal of Perinatology

JF - American Journal of Perinatology

SN - 0735-1631

IS - 4

ER -